BRIEF-Redhill Biopharma says re-submission of rizaport U.S. NDA expected in Q4 of 2016

Tue Mar 29, 2016 7:42am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

March 29 (Reuters) - Redhill Biopharma Ltd

* Re-Submission of rizaport U.S. New drug application (NDA) to FDA and receipt of a new pdufa date are expected in Q4 of 2016 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)